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Abstract: The combination of different therapies into a single platform has attracted 
increasing attention as a potential synergistic tumor treatment. Herein, the fabrication 
of a novel folate targeted system for chemo-photothermal therapy by using 
thioether-bridged periodic mesoporous organosilica nanoparticles (PMOs) as a 
drug-loading vehicle is described. The novel targeted molecular bovine serum 
albumin-folic acid-modified MoS2 sheets（MoS2-PEI-BSA-FA）were successfully 
synthesized and characterized, and then utilized as a capping agent to block PMOs to 
control the drug release and to investigate their potential in near-infrared photothermal 
therapy. The resulting PMOs–DOX@MoS2–PEI-BSA-FA complexes had a uniform 
diameter (196 nm); high DOX loading capacity (185 mg/g PMOs-SH); excellent 
photothermal transformation ability; and good biocompatibility in physiological 
conditions. The PMOs–DOX@MoS2–PEI-BSA-FA exhibited pH-dependence and 
near infrared (NIR) laser irradiation-triggered DOX release. In vitro experimental 
results confirmed that the material exhibits excellent photothermal transfer ability, 
outstanding tumor killing efficiency and specificity to target tumor cells via an 
FA-receptor-mediated endocytosis process. The in vivo experiments further 
demonstrated that the platform for synergistic chemo-photothermal therapy could 
significantly inhibit tumor growth, which is superior to any monotherapy.  
Meanwhile, cytotoxicity assays and histological assessments show that the engineered 
PMOs@MoS2–PEI-BSA-FA have good biocompatibility, further inspiring potential 
biomedical applications. Overall, this work describes an excellent drug delivery 
system for chemo-photothermal synergistic targeted therapy having good drug release 
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properties, which have great potential in cancer therapy. 
Keywords: Synergistic therapy, periodic mesoporous organosilica, MoS2, cancer 
cell targeting, drug delivery 
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1. Introduction 
Nanomaterial-based drug delivery systems are increasingly promising and useful 
as tools in cancer therapy. Mesoporous silica nanoparticles (MSNs) have been used as 
carrier systems for drug delivery due to their nontoxic nature, high surface area, large 
pore volume, tunable pore size and chemically modifiable surfaces [1-3]. Since their 
discovery in 1999, periodic mesoporous organosilica (PMOs), as a new type of MSNs 
with an organic group-incorporated, are considered one of the most important 
developments in this area of research [4,5]. Similar to MSNs, PMOs prepared from 
organo-bridged alkoxysilanes have tunable mesopores [6]. However, unlike the 
surface-functionalized MSNs, the porous frameworks of PMOs are based on organic 
functional groups covalently linking siloxane domains [7-10]. Consequently, the 
organic moieties in the PMOs are built directly into the walls of the channels that 
could be utilized for many applications such as gas and molecule adsorption, catalysis, 
drug and gene delivery, electronics and sensing [11-14]. Guo et al. reported that 
Rhodamine B loaded ethylene-bridged HPMOS NPs functionalized with 
pH-responsive supramolecular nanovalves enabled the controlled release of the 
Rhoadamine B at pH 4 or 10 in water and/or in acetonitrile [15]. The first in vitro 
studies on the delivery of drugs were published in 2013 [12] and Lin et al. reported a 
controlled drug release system based on PMOs [16]. Numerous PMO-based 
controlled release systems have been reported that perfect control over the drugs, 
achieved largely in the presence of bridged silane with contrary functionality with 
drug molecules at the pore channels or wall structure [17-21]. Also, preliminary 
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studies have reported that the PMOs are biodegradable and have better 
hemo-compatibility than pure mesoporous silica nanoparticles [22,23]. 
Despite these burgeoning developments, it is still a challenge to produce more 
general and practical bio-responsive controlled-release PMOs systems. The major 
problem is that the drugs encapsulated via a non-covalent force often exhibit 
undesirable premature release during circulation but grafting suitable capping agents 
onto the surface of PMOs can prevent such problems. Recent reports on the design of 
capped MSNs have used inorganic nanoparticles [24], polymers [25], peptides [26], 
drugs [27] and nucleic acid [28] as caps to block the pore entrances of the MSNs.  
Although there have been considerable successes in the design of capping agents 
some drawbacks including low drug loading efficiency and limited targeting 
properties greatly hinder their applications in cancer therapy. 
Synergistic therapies are attracting increasing attention in the field of cancer 
treatment [29,30] and the combination of photothermal therapy with chemotherapy 
can further enhance the performance in cancer treatment [31-33]. In particular, 
two-dimensional (2D) transitional metal dichalcogenide (TMDC) nanosheets, such as 
MoS2, WS2, MoSe2 and WSe2, have received much attention due to their unique 
electronic, physical and chemical properties [34]. Among them, MoS2 is an excellent 
material for biomedical applications because molybdenum is an essential trace 
element for several cell enzymes and sulfur is a common biological element [35,36].  
There have been a number of previous reports using MoS2 in the area of biomedicine 
owing to its good biocompatibility and high photothermal performance as shown by 
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graphene being used to wrap MSNs, gold nanoparticles and gold nanorods [37-41]. 
Considering the similarities in the morphology and properties between graphene and 
MoS2 the latter, in the form of nanosheets, has been investigated as a capping agent to 
wrap PMOs for drug delivery. Also, because of the excellent photothermal properties 
of MoS2 it can act as a thermal gatekeeping coat on PMOs resulting in the design of a 
novel nanoplatform with photo-triggered drug release and producing synergistic 
chemo-photothermal therapy. A recent study by Liu et al. reported 
transferrin-decorated and MoS2-capped hollow mesoporous silica nanospheres, which 
show high loading and outstanding chemo–photothermal synergetic efficacy for 
cancer therapy [42]. However, to the best of our knowledge, there is no report on the 
validation of both in vitro and in vivo therapeutic effects of these nanoplatforms. 
Generally, designing a multifunctional platform with photothermal ability and 
targeting properties would be an efficient way to improve the accumulation of 
chemotherapy drugs, to reduce side effects and synergistically enhance the therapeutic 
effects. With this in mind, a multifunctional platform based on a functionalized-MoS2 
nanosheet wrapped PMOs was designed for both targeting drug delivery and 
synergistic chemo-photothermal therapy and is now reported in the present work 
(Scheme 1). PMO nanoparticles，which have a low density, a uniform diameter (196 
nm), a BET surface area of 1023.04 m2/g, a pore volume of 1.06 cm3/g, and a uniform 
pore diameter (D) of 3.84 nm and excellent biocompatibility were first prepared. The 
chemotherapy drug, DOX, was then loaded into the channels of the PMOs (185 mg 
DOX per gram of PMOs-SH) and, for the first time, single-layer MoS2 nanosheets 
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were prepared followed by modification with folic acid. The MoS2-LA-BSA-FA 
complex then acted as capping agent to block PMOs via electrostatic interactions and 
weak thiol reactions.  The drug-release behavior showed that the encapsulated DOX 
in the PMOs–DOX@MoS2–LA-PEI-BSA-FA could be controllably released using 
808 nm laser irradiation and because of the specific recognition of the FA receptor and 
MCF-7 expressed on tumor cells, the complexes exhibited excellent targeting ability. 
Both in vitro and in vivo experiments demonstrated that the 
PMOs–DOX@MoS2–LA-PEI -BSA-FA nanocomposite has an excellent cancer cell 
killing effect by combined photothermal and chemotherapy, suggesting that the 
PMOs-based synergistic strategy has great potential in cancer therapy. 
 
Scheme 1. Schematic illustration for the synthesis and preparation of 
PMOs–DOX@MoS2–LA-PEI-BSA-FA composite as a multifunctional drug delivery 
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system for synergistic chemo-photothermal targeted therapy of tumors. 
 
2. Materials and methods 
2.1. Materials  
Cetyltrimethyl ammonium bromide (CTAB), tetraethoxysilane (TEOS), 
concentrated ammonia (25 wt %) and anhydrous ethanol were purchased from 
Sinopharm Chemical Reagent Co., Ltd (Shanghai, China). Bulk MoS2 powder (2-8 
µm, 99%), 3-mercaptopropyltrimethoxysilane (MPTMS), DOX hydrochloride and 
1,4-bis- (triethoxysilyl) propane tetrasulfide (TESPTS) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA).  n-BuLi hexane solution (2.4 M), alpha-lipoic 
acid (LA), folic acid (FA), N-hydroxysuccinimide (NHS), 
N-[3-(dimethylamino)propyl]-N′-ethyl-carbodiimide hydrochloride (EDC), 
2-(N-morpholino)ethanesulfonic acid（MES）, polyethylenimine (PEI, Mw = 25 kDa) 
and bovine serum albumin (BSA) were purchased from Aladdin Reagent (Shanghai, 
China).  Dimethyl sulfoxide (DMSO), fetal bovine serum (FBS), phosphate buffered 
saline (PBS), antibiotics (penicillin/streptomycin) and DMEM media were supplied 
by the Shanghai Pumai Biotechnology Co. Ltd. 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 
4′-6-diamidino-2-phenylindole (DAPI) was purchased from Nanjing Keygen Biotech.  
The human cancer MCF-7 cell lines and human hepatoma 7402 cells were provided 
by the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. 
Deionized water (H2O) used in all experiments was purified by a Millipore system 
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(Milli-Q, 18.2 MΩ cm). 
2.2. Synthesis of PMOs-SH 
The thioether-bridged PMOs were prepared according to the surfactant directed 
sol–gel method. CTAB (0.12 g) was dissolved in a mixture of concentrated aqueous 
ammonia solution (1 mL, 25 wt %), ethanol (30 mL) and water (75 mL). The solution 
was heated to 35 oC for 1 h, and then TESPTS (0.1 mL) and TEOS (0.22 mL) was 
quickly added under vigorous stirring. The above mixture was stirred for 24 h at 35 oC, 
the white product was collected by centrifugation at 10000 rpm for 10 min, washed 
three times with ethanol and suspended in ethanol (250 mL) and concentrated HCl 
(0.6 mL ) at 60 °C for 3 h to remove the CTAB surfactants. 
For the synthesis of PMOs-SH, the prepared PMOs (50 mg) was dispersed in 
ethanol (150 mL). Then, 3-mercaptopropyltrimethoxysilane (MPTMS; 0.15 mL) and 
25 wt % aqueous ammonia solution (0.2 mL) were added and stirred overnight and 
the PMOs-SH was collected by centrifugation and washed three times with deionized 
water. 
2.3. Synthesis of MoS2 nanosheets  
Multilayered MoS2 was exfoliated by the Morrison method [43] whereby MoS2 
flake (2 g) was stirred with hexane solution (2 mL) of n-buthyllithium (1.6 M) for 48 
h in an N2 atmosphere. Following the intercalation by lithium, the mixture was 
washed with hexane to remove residual n-buthyllithium and water (30 mL) was added.  
The MoS2-containing water solution was ultrasonicated for 90 min to allow effective 
exfoliation and then centrifuged at 3000 rpm to remove the multilayered MoS2 
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nanosheets and excess LiOH in the precipitates. The exfoliated MoS2 was dialyzed 
using a cellulose membrane (MWCO: 10 kDa) for 3 d, then stored as a solution in 
water. Table S1 gives a summary of the different reaction conditions investigated and 
the best yield (51.6%) was obtained with 1.6M n-buthyllithium and 90 min 
sonication. 
2.4. Synthesis of MoS2-PEI–BSA–FA composites.  
The outline process for the preparation of MoS2-PEI–BSA–FA composites is 
shown in Scheme S1a-b. EDC (260 mg) and NHS (158.8 mg) were added to α−lipoic 
acid (114.4 mg) dissolved in acetonitrile（25 mL）under vigorous stirring. After 30 min, 
a solution of PEI (0.5 g) dissolved water (40 mL) with the pH adjusted to 7.4 with 
dilute hydrochloric acid was added and the solution stirred overnight at room 
temperature. The resulting product was dialyzed using a cellulose membrane (MWCO: 
1 kDa) in pure water for 24 h and then lyophilized to obtain the LA-PEI. The resulting 
LA–PEI (30 mg) was added into a MoS2 dispersion in water (10 mL; 0.3 mg.mL-1) 
with 30 min sonication and vigorous stirring to form MoS2-LA-PEI.  In order to 
remove minor impurities, the product was dialyzed (MWCO: 3500 Da, 4000 rpm, 10 
min) with 0.5 M NaCl containing phosphate buffer (20 × 10−3 M) three times and 
washed with pure water. The final product was stored at 4 °C in water. 
The BSA–FA complexes were fabricated following a literature approach as 
depicted in Scheme S1c [44]. Typically, folic acid (1 mL; 5 mM) in MES buffer 
solution (5mL; 50 mM; pH 6) was reacted in the dark with EDC (3 mg) and NHS (3 
mg) for 20 min. Then the activated FA solution (500 µL; 5 mM) solution was mixed 
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with BSA (100 mL; 5 µM) and left to stir overnight. Finally, the product was dialyzed 
for 24 h against MES buffer with a cellulose membrane (MWCO 3500 Da) to remove 
unreacted FA and reaction by-products. The resulting BSA–FA solution (40 mL) was 
then mixed with the aqueous solution of MoS2-LA-PEI followed by the addition of 
EDC (48 mg) and NHS (28 mg) with stirring for 12 h.  This mixed solution was then 
centrifuged for 15 min at 5000 rpm and washed with water (3 times). Finally, the 
MoS2-PEI–BSA–FA nanocomposites were re-suspended in PBS (pH 7.4) solution for 
further use. 
2.5. Preparation of PMOs–DOX@MoS2-PEI–BSA–FA  
PMOs-SH (20 mg) was sonicated for 20 min in PBS solution (10 mL) followed 
by the addition of DOX dissolved in PBS solution (10 mL: 1 mg/mL) and the 
suspension was stirred in the dark for 24 h at room temperature. The mixture was 
centrifuged and washed with PBS (40 mL) and water several times. All supernatants 
and washed solutions were collected in order to determine the amount of drug loaded 
using UV-Vis spectrophotometry (482 nm). Finally, the resulting solid material was 
re-suspended in water (10 mL) and sonicated with a MoS2-PEI–BSA–FA solution (5 
mL: 1.45 mg/mL) for 4 min. The mixture was centrifuged at 11000 rpm for 15 min 
and then washed with water (three times) to remove any free MoS2-PEI–BSA–FA and 
the targeted MoS2-wrapped PMOs–DOX (PMOs–DOX@MoS2-PEI–BSA–FA) was 
obtained after drying at 60 oC under vacuum. The loading content (LC, w/w%) of 
DOX were calculated by use of the following equation: 
LC= (weight of loaded DOX) / (total weight of nanocomposites) ×100%      Eqn 1 
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2.6. Characterization 
Transmission electron microscopy (TEM) was performed on a JEOL JEM-2010 
instrument with an acceleration voltage of 200 kV. The surface topology of the 
obtained materials was analyzed using field emission scanning electron microscopy 
(SEM, S-4800, Japan, Hitachi). The thickness and size of the MoS2 were measured 
with an Agilent 5500 atomic force microscope (AFM, USA) under ambient conditions. 
Dynamic light scattering (DLS) and zeta potential measurements were performed on a 
Malvern Zetasizer Nano ZS instrument (ZS90, UK). UV-vis absorption spectra were 
recorded on a UV-1800 spectrophotometer (Shanghai JingHua Instruments). XRD 
measurements were performed on a Bruker D8 Advance X-ray diffractometer 
equipped with graphite-monochromatized Cu Kα radiation (λ=1.5418 Å). Fourier 
transform infrared (FT-IR) spectra were recorded on a Nicolet Nexus 870 
spectrometer (Nicolet Instruments Inc. Madison, WI, USA). Nitrogen sorption 
isotherms were measured by a Micromeritics Tristar 3000 analyzer (Micromeritics 
Instruments Corporation, Atlanta, GA, USA). The Mo concentration was determined 
with a Leeman Prodigy inductively coupled plasma-atomic emission spectroscopy 
(ICP-AES) system (Hudson, NH03051, USA). The photothermal conversion 
efficiency of the materials were analyzed using a laser device (Shanghai Xilong 
Optoelectronics Technology Co. Ltd., Shanghai, China) at a wavelength of 808 nm 
and the temperature of the solution was monitored using a DT-8891E thermocouple 
linked to a digital thermometer (Shenzhen Everbest Machinery Industry, Shenzhen, 
China). 
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2.7. Photothermal effect of PMOs–DOX@MoS2-PEI–BSA–FA  
In order to measure the photothermal effects, various concentrations of the 
nanocomposites in PBS (pH 7.4) were irradiated using an 808 nm laser (1 W/cm2).  
The influence of laser power density on the photothermal effect was ascertained by 
irradiating a solution of the PMOs–DOX@MoS2-PEI–BSA–FA (1 mg/mL) under 
different power densities; the changes in temperature were measured using 
PMOs-DOX and PBS as control groups under the same conditions. The thermal 
stability of PMOs–DOX@MoS2-PEI–BSA–FA samples was determined by irradiating 
for 5 min each time with five on-off cycles. Meanwhile, the temperature changes of 
the different materials under continuous NIR laser irradiation (1 W/cm2) for 5 min 
were recorded by using an infrared (IR) thermal imaging system. The photothermal 
conversion efficiency of PMOs–DOX@MoS2-PEI–BSA–FA was calculated by the 
following equation [45]: 
Eqn 2   
 
Where, h is the heat transfer coefficient, S is the surface area, Tmax is equilibrium 
temperature, Tam is surrounding ambient temperature, Q0 is heat absorption of the 
quartz cell, I is the laser power and A is the absorbance of the materials at 808 nm. 
2.8. In vitro drug release  
A dispersion of PMOs–DOX@MoS2-PEI–BSA–FA in PBS (pH 7.4 or pH 5.0) 
with a PMOs concentration of 1 mg mL-1 was introduced into a dialysis bag (Mw = 
8-10 KDa) and then dialyzed against different PBS solutions (40 mL) with exposure 
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to 808 nm laser irradiation (1 W/cm2) with shaking (150 rpm) for 10 min. A sample of 
media released (1 mL) was collected at different time intervals, and an equal volume 
of fresh buffer was added. The concentration of DOX released was determined by 
using UV−vis spectrophotometry (484 nm). The control group was treated under 
identical conditions but without irradiation. The cumulative amount of released DOX 
from the composites was calculated. 
2.9. Cell culture and cytotoxicity assay  
MCF-7 cells were cultured in DMEM medium with 10% FBS, 1% penicillin, 
and 1% streptomycin in a 5% CO2 incubator at 37 oC. The cytotoxicity was quantified 
by a MTT assay using MCF-7 cells which were seeded in a 96-well plate at 5×103 
cells per well with 100 µL of DMEM medium. The plate was loaded into an incubator 
at 37 oC under a 5% CO2 atmosphere for 24 h. The culture medium was removed and 
replaced with fresh medium (150 µL) containing different concentrations of 
PMOs-SH or free DOX and the cells were incubated in fresh medium for another 24 h 
and the MTT solution (100 µL: 5 mg/mL in culture medium) was added. Following 
incubation for 4 h, the MTT/medium was replaced by DMSO (150 µL) for 20 min to 
dissolve the formazan crystals. Finally, the absorbance of the solution was determined 
at 570 nm using a microplate reader (BioTek). Each experiment included six wells for 
each different condition. 
2.10. In vitro cellular uptake  
Cell targeted efficiency was investigated by utilizing confocal laser scanning 
microscopy (CLSM) observation and flow cytometry analysis. MCF-7 cells (Folic 
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acid (FA) receptor positive) and hepatoma 7402 cells (FA receptor negative) were 
seeded at a density of 1×105 cells per well in 24-well plates and cultured for 24 h.  
All cells were treated with PMOs–DOX@MoS2-PEI and 
PMOs–DOX@MoS2-PEI–BSA–FA at a DOX concentration of 5 µg mL-1 for 4 h 
followed by washing the cells with PBS. The NIR treated group was irradiated with a 
laser（808 nm）for 5 min at 1.0 W cm−2. The cells in all the groups were cultured for 
another 2 h and then washed and fixed with 4% formaldehyde for 30 min. The cell 
nuclei were stained with DAPI and observed by confocal laser scanning microscopy 
(CLSM, Jena, Germany) equipped with a 63× oil immersion lens. 
To correlate the cellular uptake behavior and cell apoptosis by the NPs, MCF-7 
cells at a concentration of 1 ×105 cells were allowed attachment growth for 24 h.   
They were then treated with PMOs–DOX@MoS2-PEI and the composite NPs with 
PMOs–DOX@MoS2-PEI–BSA–FA (DOX concentration of 5 µg/mL) for 12 h with or 
without 5 min laser irradiation after 2 h incubation. The number of cells that showed 
early apoptosis (positive for FITC-labeled Annexin V), late apoptosis (double positive 
for FITC-labeled Annexin V and propidium iodide), and necrosis (positive for 
propidium iodide) were analyzed by flow cytometry (Becton Dickinson, CA, USA) 15 
with untreated cells utilized as blank controls. 
Specific cellular uptake of the PMOs–DOX@MoS2-PEI–BSA–FA within MCF-7 
cells and hepatoma 7402 cells was also demonstrated by quantitative ICP-AES 
analysis. Both MCF-7 and hepatoma 7402 cells were seeded in a 24-well plate at a 
density of 5 × 105 cells/well and incubated for 24 h. The medium was replaced with 
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fresh medium containing PMOs–DOX@MoS2-PEI–BSA–FA and the cells were then 
incubated for 12 h at 37 oC and 5% CO2. The cells were washed 3 times with PBS, 
trypsinized, centrifuged, and re-suspended in PBS. The cell suspensions (100 µL) 
were counted and the remaining cells were centrifuged to form pellets and lysed using 
an aqua regia solution (0.5 mL) to digest both the cells and the nanoparticles. The 
digested sample was then diluted with PBS (1.5 mL) and the intracellular 
concentration of Mo in MCF-7 and hepatoma 7402 cells was quantitatively measured 
using ICP-AES. 
2.11. Synergistic effects of photothermal therapy and chemotherapy 
in vitro  
MCF-7 cells were cultured in a 96-well plate at 5×103 cells per well for 24 h, and 
the next day, were co-cultured with PMOs–DOX@MoS2-PEI–BSA–FA (suspended in 
medium) or PMOs@MoS2-PEI–BSA–FA. Cells were divided into six groups: group 1 
PBS（control）; group 2 PMOs @MoS2-PEI-BSA-FA; group 3 free DOX; group 4 
PMOs@MoS2-PEI-BSA-FA+NIR (photothermal therapy); group 5 
PMOs-DOX@MoS2-PEI-BSA-FA nanoparticles (chemotherapy); and group 6 
PMOs-DOX@MoS2-PEI-BSA-FA+NIR (synergistic therapy). After incubation for 12 
h, the cells were washed with PBS and culture medium was then added to the wells. 
The cells were irradiated with a laser (808 nm, 1.0 W cm-2) for 5 min for 
photothermal and synergistic treatments, and then all the cells were cultured for 24 h 
and an MTT assay was used to measure cell viability. 
2.12. In vivo experiments  
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All the animal experiments were performed in agreement with the guidelines of 
the Institutional Animal Care and Use Committee. Female athymic nude mice aged 4 
to 6 weeks were purchased from Nanjing PengSheng Biological Technology Co., Ltd 
and subcutaneously injected with 1×106 MCF-7 cells per mouse. When the tumors 
reached 50 mm3 after cell inoculation, the animals were divided randomly into 6 
groups (n = 6 for each group). Each mouse was intravenously injected, via the tail 
vein, with either: saline (control), PMOs-DOX@MoS2-PEI–BSA–FA (chemotherapy), 
free DOX (3 mg/kg), PMOs@MoS2-PEI–BSA–FA+NIR (photothermal therapy), 
PMOs–DOX@MoS2-PEI+NIR, PMOs–DOX@MoS2-PEI–BSA–FA+NIR 
(synergistic therapy). The tumors of NIR groups were irradiated with the NIR laser (1 
W cm−2) for 5 min on the second day (at 24 h post-injection). The body weight and 
the tumor volume was measured every 2 days after irradiation and reported as V = 
W2×L/2, where W and L are the width and length diameters, respectively. 
The biodistribution of PMOs-DOX@MoS2-PEI–BSA–FA in the tumor-bearing 
mice was investigated by ICP-AES. A PMOs-DOX@MoS2-PEI–BSA–FA PBS 
suspension (0.1 mL; 2 mg/mL) was intravenously injected into the mice.  Then the 
mice were scarified at 12 h post-injection, and the organs were excised, lyophilized, 
weighted and digested by aqua regia for ICP-AES measurements to determine the Mo 
content. To compare the difference in the MoS2 uptake between the 
PMOs-DOX@MoS2-PEI–BSA–FA and PMOs-DOX@MoS2-PEI, the organs and the 
tumor tissue 12 h post-injection of PMOs-DOX@MoS2-PEI were extracted and the 
Mo concentration in those organs was quantified in a similar way.  
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2.13. Blood biochemistry and pathology  
After 20 days of treatment, the representative mice from the six groups were 
sacrificed to harvest the tumors and the major organs including the heart, liver, spleen, 
lungs, and kidneys. The tumors and organs were fixed, embedded, sectioned and 
stained with hematoxylin and eosin (H&E) before optical microscopic observation. 
Blood samples were collected from the eye vein by removing the eyeball quickly. 
After 3 h standing at 4 °C, the collected blood samples were centrifuged at 1000 rpm 
for 3 min to obtain serum. The blood biochemistry analysis was determined using a 
fully automatic biochemistry analyzer (ADVIA2400, Siemens, USA). 
2.14. Statistical analysis 
Every experiment was repeated three times and the results are shown as the mean 
SE ± SD. Graph Pad Prism software was used for the statistical analysis. Student’s 
t-test was used to compare two independent groups of data and P < 0.05 was 
considered significant. 
3. Results and discussion 
3.1. Synthesis and characterization of nanocomposites  
Scheme 1 illustrates the strategy for the construction of the hybrid nanocarriers 
PMOs–DOX@MoS2-PEI–BSA–FA. The thioether-bridged PMOs nanospheres were 
synthesized by a CTAB-directed sol–gel process followed by modification of the thiol 
bonds in a MPTMS solution. MoS2 nanosheets were obtained by chemical exfoliation 
using a previously reported [38] chemical method which was optimized by varying 
the reaction conditions as shown in Table S1. The highest yield obtained reached 
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51.6%, which is close to the reported research [46]. The MoS2 surface was 
functionalized with LA–PEI (synthesized by a simple amide coupling) which has two 
sulfur atoms in the LA moiety enabling much stronger binding to the sulfur areas in 
the MoS2 and the LA–PEI (Fig. S1a-b, Supporting Information). MoS2–PEI was then 
formed by sonication of MoS2 with LA-PEI，which was then selectively conjugated 
onto the outer surfaces of PMOs-DOX or PMOs-SH. MoS2 is remarkably stable and 
efficiently prevents leakage of the loaded drug. Due to the introduction of amino 
groups from the PEI, the nanoparticles are functionalized with BSA–FA complexes 
(Fig. S1c, Supporting Information) through the formation of amide bonds to improve 
the stealthiness of the nanocarriers under physiological conditions and the capability 
to target cancer cells [47]. After selective uptake of the nanocarrier via FA receptor 
mediated endocytosis the nanoparticles are trapped inside the endosome. Under laser 
irradiation, the MoS2 transforms NIR light into heat and the local high temperature 
leads to the expansion and vibration of the MoS2 sheets and the PMOs, causing DOX 
release.  
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Fig. 1. (a, b）TEM images of thioether-bridged product synthesized by the sol–gel 
method followed by MPTMS modified PMOs; (c, d) TEM images of PEI modified 
MoS2-wrapped DOX-loaded PMOs (PMO–DOX@MoS2-LA-PEI); the blue arrow in 
(c,d) indicates the MoS2 nanosheets on PMOs; (e) AFM topography images of the 
as-exfoliated MoS2 nanosheets and (f) the corresponding height profile. 
The TEM images (Fig. 1a-b) show that the prepared PMOs have well-defined 
spherical nanostructures with a diameter of approximately 196 nm. In addition, the 
SEM images reveal that PMOs have similar spherical morphology with an average 
diameter around 200 nm (Fig. S1, Supporting Information), which is further verified 
by the particle size distribution of PMOs measured by TEM. The structures of the 
PMOs were also studied by X-ray diffraction (XRD) and the XRD pattern shows a 
strong peak at 2.26o, suggesting the PMOs have an ordered mesostructure (Fig. S2, 
Supporting Information). The results of the N2 adsorption−desorption isotherm and 
pore size distribution curve (Fig. S3, Supporting Information) indicated that the 
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PMOs-SH possess a large BET surface area (1023.04 m2/g), a pore volume of 1.06 
cm3/g, and uniform pore diameter (D) of 3.84 nm. The mercaptopropyl groups in the 
thiol-modified PMOs were identified by Raman spectroscopy with the C-H stretching 
of the CH2 groups appearing at 2931 cm-1. The Si-C bond stretching can be identified 
at 1424 cm-1 and the Si-O-Si bond vibration is at 786 cm-1. Other vibrations are 
observed at 1328 cm-1 (symmetric deformation of the CH-S group) and 621 cm-1 (C-S 
bond stretching) indicating the existence of sulfydryl groups in the PMOs-SH. 
Furthermore, as shown in the FT-IR spectra (Fig. S4, Supporting Information), the 
PMOs-SH (black line) demonstrate the characteristic C-H bonds at 2831 cm−1; the 
C-S bond at 682 cm-1; and an -SH bond at 576 cm-1, all of which is consistent with the 
published literature [17]. After DOX was loaded into the PMOs (red line), the 
absorption at 1695 cm-1, which can be assigned to C=O stretching of DOX, also 
verifies that the desired materials were successfully prepared. In addition, the 
DOX-loading capacity reached 185 mg DOX per gram of PMOs-SH. 
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Fig. 2. (a) Raman spectra of thiol-modified PMOs; (b) Zeta potentials of PMOs-SH, 
PMOs-DOX, MoS2 nanosheets, MoS2-LA-PEI, PMOs-DOX@MoS2-PEI, and 
PMOs-DOX@MoS2-PEI-BSA-FA in distilled H2O; (c) UV-Vis absorption spectra of 
the PMOs, PMO–DOX, MoS2, and PMO–DOX@MoS2-PEI-BSA-FA; and (d) 
Hydrodynamic diameters of the PMOs-SH, PMO–DOX@MoS2, and 
PMO–DOX@MoS2–PEI-BSA-FA. 
After the PMOs-DOX was mixed with the targeted-MoS2 under sonication in 
water for a few minutes PMOs–DOX@MoS2-PEI–BSA–FA was obtained. As 
revealed by TEM (Fig. S5, Supporting Information) the prepared MoS2 nanosheets 
were mostly single-layer sheets with sizes in the range 120–300 nm. AFM imaging 
revealed that the MoS2-LA-PEI flakes have a thickness of about 1.5-2 nm, which 
corresponds to a single layer（Fig. 1e-f). The TEM images (Fig. 1b-c) show that MoS2 
nanosheets were successfully wrapped around the surface of the PMOs–DOX. Zeta 
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potential analysis was performed to investigate the changes in surface charge of the 
prepared nanocomposites during the whole process. The zeta potential of PMOs-SH 
was −19.0 mV, which changed to +47.6 mV when loaded with DOX. The MoS2 
flakes exhibited a zeta potential of -45.0 mV, which changed to -13.5 mV on coating 
with LA-PEI. The formation of PMOs-DOX@MoS2-PEI still showed a positive 
potential of +26.1 mV and, after BSA–FA grafting, the zeta potential of the resulting 
PMOs–DOX@MoS2-PEI–BSA–FA dropped to 6.8 mV, further confirming the 
successful loading of DOX, the wrapping of MoS2 and modification of the targeted 
region. The UV-Vis absorption spectrum of the PMOs–DOX@MoS2-PEI–BSA–FA 
indicates the presence of MoS2 nanosheets with the absorption peaks at 255 nm, 
further demonstrating the successful wrapping of MoS2 around the PMOs–DOX (Fig. 
2c).  Furthermore, the absorption peak of DOX (484 nm) in PMOs–DOX, indicates 
that the drug had been loaded into the PMOs. Meanwhile, the presence of the folate 
functionality was confirmed by the UV spectrum of 
PMOs–DOX@MoS2-PEI–BSA–FA showing the characteristic folic acid absorption 
peak at 362 nm. Thus, this, along with the absorption peaks of MoS2 nanosheets 
shows that the MoS2-PEI–BSA–FA was successfully prepared. Additionally, 
PMOs–DOX@MoS2-PEI–BSA–FA display strong absorbance in the NIR region, 
while PMOs show virtually none in that region, demonstrating the potential of 
targeted-MoS2 as a photothermal therapy on irradiation. The IR spectrum of the folic 
acid conjugate (Fig. S4a, Supporting Information) shows a strong alkyl C−H stretch at 
2850 cm−1 and the bonds at 1504 cm-1 from the FA molecule. The vibration bands at 
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1705 and 3450 cm−1 indicate successful folic acid binding, which is due to the linkage 
between the NH2 group of the folic acid conjugates and the COOH group of the BSA.  
Furthermore, some characteristic bands of PMOs-DOX had almost disappeared 
indicating the modified-MoS2 wrapping. The hydrodynamic diameters of the 
nanocomposites were verified by dynamic light scattering (DLS). After wrapping 
with the MoS2 nanosheets, the hydrodynamic diameter of the resulting 
PMOS–DOX@MoS2–PEI–BSA–FA is 314 nm, which is increased compared to 
PMOs–SH (259 nm). The size difference of the PMOs–DOX@MoS2–PEI–BSA–FA 
and PMOs-SH measured by TEM and DLS is mainly attributed to the presence of 
water [15]. In addition, the PMOs–DOX@MoS2–PEI–BSA–FA showed higher 
colloidal stability and were well dispersed in water, PBS and cell culture medium 
without any agglomeration even after 12 h on standing (Fig. S6, Supporting 
Information). Meanwhile, the colloidal stability of 
PMOs–DOX@MoS2–PEI–BSA–FA was further investigated by measuring the 
hydrodynamic size. Clearly, the hydrodynamic size of the particles do not show any 
significant changes after 7 days, suggesting that the developed 
PMOs–DOX@MoS2–PEI–BSA–FA nanoparticles possess good colloidal stability. 
3.2. Photothermal effect  
Owing to the ability of PMOs–DOX@MoS2–PEI–BSA–FA nanoparticles to 
convert NIR light energy into heat, the photothermal conversion efficiency was 
investigated by measuring the dispersion temperature under 808 nm NIR irradiation.  
As shown in Fig. 3a, a concentration-dependent photothermal heating effect (1 W/cm2 
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for 5 min) is observed and Fig. 3b shows the laser-power-dependent photothermal 
effect with different irradiation power densities of the 
PMOs–DOX@MoS2–PEI–BSA–FA (1 mg mL-1). In contrast to the negligible 
temperature change of pure water, a significant increase to 53.7 °C was observed 
when PMOs–DOX@MoS2–PEI–BSA–FA (2.0 mg mL-1) was irradiated for 5 min at 
1.0 W·cm−2, indicating suitability for photothermal therapy [31]. In comparison, 
PMOs–DOX solutions without MoS2 wrapping showed an unexplainable temperature 
rise at the same irradiation conditions. Also, with the increase of laser power density 
from 0.5 to 2.0 W·cm−2 (Fig. 3b) the temperature of the dispersion is also remarkably 
enhanced and the dispersion shows excellent photothermal stability, confirming it as a 
promising candidate for photothermal therapy with five on/off cycles of laser 
irradiation (Fig. 3c). As shown in Fig. 3d, the solution temperatures of MoS2 and 
PMOs-DOX@MoS2-PEI-BSA-FA both increased rapidly under the 808 nm laser 
irradiation (1 W/cm2) and reached 50.7 °C and 45.8 °C respectively, within 5 min at 
the same MoS2 concentration. In comparison, the water and PMOs-DOX solution 
remained below 30 °C under the same laser irradiation. Meanwhile, the photothermal 
conversion efficiency of PMOs–DOX@MoS2–PEI–BSA–FA was calculated to be 
62.5% and the linear regression curve is shown in Fig. 3e. 
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Fig. 3. (a) Temperature variation curves of the PMOs–DOX@MoS2–PEI-BSA-FA 
solutions with different concentrations at a laser power density of 1 W cm-2 for 5 min.  
(b) Temperature variation curves of the PMOs–DOX@MoS2–PEI-BSA-FA solution 
at different laser power densities for 5 min. (c) Temperature plot of 
PMOs–DOX@MoS2–PEI-BSA-FA solution irradiated by an 808 nm laser (2 W cm−2) 
for five on–off cycles. (d) Photothermal images of water, PMOs-DOX, MoS2, and 
PMOs–DOX@MoS2–PEI-BSA-FA suspensions under continuous NIR laser 
irradiation (1 W/cm2) for 5 min. (e) The linear regression curve between the cooling 
stage and negative natural logarithm of driving force temperature of 
PMOs–DOX@MoS2–PEI-BSA-FA. (f) DOX release profiles from 
PMOs–DOX@MoS2–PEI-BSA-FA nanocomposites at different pH with or without 
NIR laser irradiation (808 nm, 1 W/cm2). 
3.3. Drug release in vitro  
To evaluate the potential of using PMOs–DOX@MoS2–PEI–BSA–FA as a drug 
delivery system, the in vitro controllable drug release behavior of the nanocarrier with 
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and without laser irradiation were investigated at different time points and pHs.  The 
released DOX from the PMOs–DOX@MoS2–PEI–BSA–FA was less than 2% 
without laser irradiation after 1 h (Fig. S7, Supporting Information).  In contrast, 
DOX release exceeded 15% after 1 h laser irradiation, which was higher than that 
without irradiation.  These results indicate that the NIR light-triggered photothermal 
heating effect could promote the release of DOX. This behavior may be attributed to 
the MoS2 region inducing hyperthermia under laser irradiation, which leads to the 
vibration of the MoS2 nanosheets and PMOs-SH and consequently decreases the 
interaction between DOX and the nanoplatforms. Furthermore, the release profiles of 
DOX indicated a pH-responsive pattern. As can be seen in Fig. 3f, DOX was released 
more quickly at pH 5.0 than pH 7.4 and the cumulative release was greatest at pH 5 
with irradiation. The phenomenon can be attributed to the reduction of interaction 
(hydrophobic interaction and electrostatic interaction) of DOX with the PMOs at low 
pH, which is beneficial for tumor treatment because they are more acidic than normal 
tissues [39]. Therefore, the pH-dependent and NIR-stimulated release of DOX could 
effectively enhance the synergistic chemo-photothermal therapeutic effect for tumor 
treatment. 
3.4. Cellular uptake  
Targeted delivery is a critical requirement of nanomedicine. Nanocarriers with a 
targeting ligand can recognize and bind with the receptor expressed on the cell surface, 
which triggers receptor-mediated endocytosis and increases the level of uptake. 
MCF-7 cells (FA receptor positive) and hepatoma 7402 cells (FA receptor negative) 
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were chosen as model cancer cells to study, using confocal laser scanning microscopy, 
the capacity of FA in the cellular uptake of PMOs–DOX@MoS2-PEI–BSA–FA (Fig. 
4). Both cell lines could uptake PMOs–DOX@MoS2-PEI–BSA–FA and 
PMOs–DOX@MoS2-PEI, as shown by DAPI (blue) and DOX (red) fluorescence. Fig. 
4a and b also indicates that the cells incubated with 
PMOs–DOX@MoS2-PEI–BSA–FA exhibit much stronger DOX fluorescence than 
those of PMOs–DOX@MoS2-PEI, which confirms that the cellular uptake of 
PMOs–DOX@MoS2-PEI–BSA–FA is related to the FA receptor-mediated 
endocytosis of the MCF-7 cells. In comparison, PMOs–DOX@MoS2 -PEI–BSA–FA 
and PMOs–DOX@MoS2-PEI exhibited similar uptake and rather weak DOX 
fluorescence in the hepatoma 7402 cells, owing to the lack of an FA receptor (Fig. 4b).  
These results corroborate the view that nanocomposites modified with FA facilitate 
recognition by MCF-7 cells and enhance the cellular uptake. Flow cytometry was also 
adopted to investigate the uptake of PMOs–DOX@MoS2-PEI–BSA–FA by MCF-7 
cells and to evaluate the induction of apoptosis by chemo-photothermal treatment.  
The increased fluorescence of DOX (Fig. S8, Supporting Information) indicated the 
uptake of PMOs–DOX@MoS2-PEI–BSA–FA was higher than that of 
PMOs–DOX@MoS2-PEI, further evidencing the specific FA-mediated cancer cell 
targeting. Furthermore, the cell apoptosis by flow cytometry analysis was performed 
as shown in Fig. 5a. The PMOs–DOX@MoS2-PEI–BSA–FA treatment greatly 
increased cell apoptosis compared to just the PMOs–DOX@MoS2-PEI and the 
control and, interestingly, the laser irradiation itself had a slight effect on cell viability.  
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Incubation with PMOs–DOX@MoS2-PEI and PMOs–DOX@MoS2-PEI–BSA–FA 
for 12 h induced apoptosis up to 13.8% and 33.9%, respectively. With laser 
irradiation, the PMOs–DOX@MoS2-PEI–BSA–FA was more effective in induction 
of apoptosis than PMOs–DOX@MoS2-PEI (59.3% vs 43.1%), further verifying the 
promoted apoptosis and higher cytotoxicity of the targeted drug delivery system.  
The targeting specificity of the PMOs–DOX@MoS2-PEI–BSA–FA complexes 
was further proven by quantitative ICP-AES analysis of the Mo uptake in MCF-7 
cells and hepatoma 7402 cells (Fig. 5b). The Mo uptake in the MCF-7 cells is 1.75, 
1.9 and 1.6 times higher than that in hepatoma 7402 cells at the same concentration. 
The above results demonstrate that the cellular uptake of the 
PMOs–DOX@MoS2-PEI–BSA–FA might be via the FA-receptor-mediated 
endocytosis process. 
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Fig. 4. Confocal laser scanning microscopy of (a) MCF-7 and (b) hepatoma 7402 
cells treated with PMOs–DOX@MoS2-PEI and PMOs–DOX@MoS2-PEI–BSA–FA 
for 4 h (relative DOX = 5.0 µg/mL). (Blue fluorescence is associated with DAPI; red 
fluorescence is expressed by released DOX and DOX in the PMOs.).  
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Fig. 5. (a) Flow cytometric analysis of the apoptosis of MCF-7 cells for 12 h induced 
by PMOs–DOX@MoS2-PEI and PMOs–DOX@MoS2-PEI–BSA–FA with or without 
laser irradiation (Annexin V-FITC/PI staining; DOX concentrations 5 µg/mL). (b) 
Cellular uptake of Mo in MCF-7 and hepatoma 7402 cells treated with the 
PMOs–DOX@MoS2-PEI–BSA–FA at different concentrations for 12 h. 
3.5. In vitro cytotoxicity assays   
A MTT assay was performed to investigate the viability of MCF-7 cells after 
incubating with the various concentrations of PMOs@MoS2–PEI–BSA–FA, MoS2 or 
PMOs-SH.  As shown in Fig. 6a, both the PMOs@MoS2–PEI–BSA–FA and 
PMOs-SH nanocomposites showed no obvious cytotoxicity on MCF-7 cells, with cell 
viability remaining over 80% in the concentration range from 0.1 to 100 µg/mL.  In 
particular, the PMOs@MoS2–PEI–BSA–FA exhibits excellent cell compatibility even 
at a high concentration of 100 µg/mL. 
3.6. In vitro synergistic therapeutic efficacy  
To investigate the synergistic therapeutic efficacy of the 
PMOs–DOX@MoS2-PEI–BSA–FA against cancer cells, different treatments were 
carried out by incubation with MCF-7 cells, followed by a MTT assay. Considering 
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the low cytotoxicity of PMOs@MoS2-PEI–BSA–FA, the killing effect of 
PMOs–DOX@MoS2-PEI–BSA–FA against MCF-7 cells was measured. Fig. 6b 
shows that cell death in each group of PMOs–DOX@MoS2-PEI–BSA–FA was dose 
dependent under the same irradiation conditions. At a DOX level of 1 µg.mL−1, more 
than half of the cells were killed in the PMOs–DOX@MoS2-PEI–BSA–FA and free 
DOX groups, but in the PMOs–DOX@MoS2 group more than 70% of the cells 
survived when the DOX was 2 µg.mL−1. This may be explained by the special affinity 
of FA to the FA receptor inducing higher internalization efficiency by MCF-7 cells.  
The therapeutic efficacy of the PMOs–DOX@MoS2-PEI–BSA–FA for cancer cells 
was also investigated and it can be seen that the viability of cells with different 
treatments significantly decreased after 24 h (Fig. 6c) or 48 h (Fig. 6d), while the cell 
viability of the control groups (PBS, PMOs@MoS2-PEI–BSA–FA) showed no 
obvious decrease. The individual groups (DOX and 
PMOs–DOX@MoS2-PEI–BSA–FA) with an equivalent dose of DOX, clearly 
exhibited marked cytotoxicity (Fig. 6c,d), confirming the chemotherapy effect of 
PMOs–DOX@MoS2-PEI–BSA–FA. Meanwhile, the cell viabilities in PTT groups 
were much lower than control groups, indicating the PTT effect of the 
nanocomposites. The cell viabilities in the synergistic therapy group were much lower 
than in the monotherapy groups (chemotherapy or PTT). These significant results 
demonstrate that the synergistic therapy by PMOs–DOX@MoS2-PEI–BSA–FA can 
kill cancer cells. The information obtained from the in vitro release and cell viability 
results (Fig. 3f) demonstrates that (1) the constructed multifunctional platform is an 
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excellent controlled release system, and (2) NIR laser irradiation not only induces heat 
for photothermal therapy, but also accelerates the release of DOX from 
PMOs–DOX@MoS2-PEI–BSA–FA leading to enhanced chemotherapy. 
 
Fig. 6. In vitro antitumor activity against MCF-7 cells: (a) Cell viabilities of 
MCF-7cells incubated with PMOs-SH, MoS2 and PMOs@MoS2-PEI–BSA–FA 
nanoparticles at various concentrations. (b) Cell viability of MCF-7 cells incubated 
with different concentrations of DOX, PMOs-DOX and PMOs–DOX@MoS2-PEI– 
BSA–FA (with equivalent concentrations of DOX). (c) and (d) Cell viability of 
MCF-7 cells treated with different nanocomposite with or without 808 nm laser 
irradiation and then incubated for 24 h (c) or 48 h (d).  (The total drug content in all 
groups was kept the same). Independent-samples t test **P < 0.01, ***P < 0.001. 
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3.7. Antitumor effect in vivo  
Inspired by the excellent chemo-photothermal synergistic therapy effect in vitro 
of PMOs–DOX@MoS2-PEI–BSA–FA, the in vivo therapeutic effect was investigated 
by measuring tumor size (Fig. 7). When tumors grew to about 50 mm3 in volume, 
mice were treated with PMOs–DOX@MoS2-PEI–BSA–FA and 
PMOs-DOX@MoS2-PEI (3 mg DOX equiv./kg) and irradiated with NIR laser (808 
nm, 1 W/cm2, 5 min) at 8 h post injection. The treatment was repeated once a week 
with PMOs–DOX@MoS2-PEI–BSA–FA without NIR, PMOs@MoS2-PEI-BSA-FA 
with NIR irradiation; with free DOX and saline being used as controls. The results 
show that PMOs–DOX@MoS2-PEI–BSA–FA with NIR irradiation can inhibit tumor 
growth much better owing to the synergistic chemo-photothermal therapy (Fig. 7a-7b). 
Meanwhile, the results also showed that mice treated with 
PMOs–DOX@MoS2-PEI–BSA–FA and NIR irradiation inhibited tumor growth by 
interacting with the targeted region (FA), which was obviously more effective than 
non-targeting PMOS-DOX@MoS2-PEI under the same conditions. In addition, the 
chemotherapy group (PMOs–DOX@MoS2-PEI–BSA–FA or DOX) or photothermal 
therapy (PMOs@MoS2-PEI-BSA-FA with laser irradiation) alone can also inhibit 
tumor growth, but is not as efficacious as that in the synergistic therapy group. Free 
DOX treatment could also inhibit tumor growth but was not as effective as 
PMOs–DOX@MoS2-PEI–BSA–FA with NIR irradiation. The photographs of tumors 
isolated at day 20 from the mice treated with PMOs–DOX@MoS2-PEI–BSA–FA 
demonstrate the good antitumor efficacy in vivo (Fig. 7b). In addition, no weight loss 
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was observed in any of the groups, indicating the high bio-safety of the materials (Fig. 
7c). Meanwhile, the Kaplan–Meier survival curve showed that mice treated with 
PMOs–DOX@MoS2-PEI–BSA–FA in combination with NIR irradiation had a much 
longer survival period than for the other groups (Fig. 7D), demonstrating satisfactory 
biocompatibility and biosafety of the in vivo application.  
The bio-distribution of Mo in tumor tissue and several major organs (heart, lung, 
spleen, liver, kidney and tumor) was studied by ICP-AES at 12 h post intravenous 
injection of both PMOs–DOX@MoS2-PEI–BSA–FA and PMOs–DOX@MoS2-PEI 
(Fig. S9). Notably, the PMOs–DOX@MoS2-PEI–BSA–FA was mainly retained in the 
liver and spleen, both of which are major organs of the reticulo-endothelial system 
(RES).In addition, compared with the PMOs–DOX@MoS2-PEI, the 
PMOs–DOX@MoS2-PEI–BSA–FA appeared to have less tendency to be 
accumulated in the other major organs, but to be taken up by the tumor site. This 
further suggests that the special FA-mediated active targeting role. 
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Fig. 7. In vivo synergistic chemo-photothermal effect of 
PMOs–DOX@MoS2-PEI–BSA–FA with NIR irradiation. (a) Relative tumor growth 
curves of the MCF-7 tumor-bearing nude mice after intravenous injection of the 
various treatment samples (n = 6); *p < 0.05, **p < 0.01, and ***p < 0.001 (Student's 
t test). (b) Typical photographs of MCF-7 tumor-bearing mice on day 20. (c) The 
average body weights of mice after various treatments. (d) Morbidity-free survival 
rates of mice in different treatment groups within 43 d. 
3.8. HE staining and blood biochemistry  
The in vivo toxicity of PMOs–DOX@MoS2-PEI–BSA–FA was evaluated by 
histological analysis with H&E staining using sections obtained from the major 
organs of the mice (heart, liver, spleen, lung and kidney) as described in Section 2.12.  
As shown in Fig. 8, no obvious side effects were found in these tissues, no apparent 
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inflammation, injury, and no necrosis was observed, confirming the negligible 
long-term toxicity.  Meanwhile, blood biochemical analyses were carried out and 
various serum biochemical indicators were measured to detect the antitumor efficacy 
of the PMOs–DOX@MoS2-PEI–BSA–FA (Fig. S10, Supporting Information).  
Considering all the biochemical indicators, no statistically significant difference was 
observed between the control group and the PMOs–DOX@MoS2-PEI–BSA–FA 
groups.  Hence, the synergistic treatment does not affect the blood chemistry of mice. 
Furthermore, since ALT, AST and CRE are closely related to the functions of the 
liver and kidney of mice, the results demonstrated that no liver or kidney toxicity was 
induced by treatment, suggesting the safe application of 
PMOs–DOX@MoS2-PEI–BSA–FA in cancer therapy. 
 
Fig. 8. Representative H&E sections of organ tissues (heart, liver, spleen, lung, and 
kidney) of tumor-bearing mice after treatment with either saline, 
PMOs–DOX@MoS2-PEI–BSA–FA or PMOs–DOX@MoS2-PEI–BSA–FA + NIR. 
 
 
  
38 
 
4. Conclusions 
In summary, novel multifunctional PMOs–DOX@MoS2-PEI–BSA–FA 
platforms were successfully synthesized and then studied for synergistic 
chemo-photothermal therapy.  MoS2 nanosheets were wrapped onto DOX-loaded 
PMOs-SH and then modified with the targeting moiety BSA-FA.  The prepared 
PMOs–DOX@MoS2-PEI–BSA–FA had a uniform diameter (196 nm), high 
drug-loading capacity (185 mg.g-1 PMOs-SH), exhibited good biocompatibility and 
outstanding photothermal properties under NIR laser irradiation.  The fabricated 
multifunctional platform possess the following properties: (1) A high loading 
efficiency of DOX for chemotherapy.  (2) The MoS2 nanosheets, as the capping 
agent, block the pores of PMOs to reduce the sudden release of DOX into the blood 
and effectively absorb and convert NIR light to heat for photothermal therapy.  (3) 
The nanocomposites can be specifically delivered into MCF-7 cells via a 
receptor-mediated endocytosis pathway utilizing FA targeting. (4) The loaded DOX 
shows a significant dual stimuli-responsive release by a photo-response in an acidic 
environment. Notably, the in vitro and in vivo experimental results showed that the 
PMOs–DOX@MoS2-PEI–BSA–FA showed a synergistic chemo-photothermal 
therapy, which was significantly superior to each individual therapy. Thus, this 
outstanding multifunctional platform has the potential to be a drug delivery system for 
multimodal antitumor therapy. 
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 BSA-FA-modified MoS2 capped periodic mesoporous organosilica was 
fabricated. 
 The MoS2 can prevent the loaded drugs from leaking during the blood circulation. 
 The nanoplatforms showed excellent synergistic effect for cancer therapy. 
  The therapeutic effects were evaluated systematically both in vitro and in vivo. 
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